Burjeel Holdings

What Burjeel Holdings does

Burjeel Holdings is an Abu Dhabi-headquartered, publicly listed (ADX: BURJ) private healthcare group operating 89 assets — 20 hospitals, 43 medical centers, 15 pharmacies, and 11 other facilities — across the UAE, Oman, and Saudi Arabia, organized under a multi-brand portfolio (Burjeel, Medeor, LLH, Lifecare, Tajmeel, PhysioTherabia) that serves the full socioeconomic spectrum. The flagship quaternary facility, Burjeel Medical City in Abu Dhabi, houses specialty institutes for cancer, neuro-oncology, ophthalmology, cardiology, women's health, pediatrics, and rehabilitation, supported by advanced clinical technology including the Da Vinci XI robotic surgery system, intraoperative MRI, ECMO, bi-plane cath lab, and 4K laparoscopy. Burjeel Cancer Institute has delivered over 10,000 radiotherapy sessions annually, completed 163+ bone marrow transplants since 2022, and operates seven active clinical trials including Phase 3 ENERGIZE for thalassemia. Underlying digital infrastructure is the Oracle Health EMR platform on Oracle Cloud Infrastructure (one of the largest in MENA), with 100% Oracle Cerner integration targeted by 2027.

The company makes money primarily through inpatient and outpatient hospital services (over 7 million patient visits and 89,700+ surgeries in FY 2025), with super-specialty care (oncology, organ transplants, robotics, CAR-T, gene therapy) accounting for >30% of revenue at complex-procedure price points of AED 50,000–1,000,000. Supplementary streams include pharmacy retail, an O&M (Operations & Maintenance) management platform across the Gulf and Africa, a Claims Care unit (partnered with Claritev Corporation), and a Burjeel-e& telemedicine application. Go-to-market combines direct-to-consumer delivery through the hub-and-spoke network with medical tourism referral pathways (Etihad Airways, Axiom Space), enterprise/insurance contracts (Al Ain FC, EDGE Group, DoH, Egypt MoH, MoE), and government Emiratisation partnerships.

FY 2025 revenue reached AED 5.5 billion (~$1.5 billion, +9.8% YoY), with net profit surging 39.5% to AED 503 million, EBITDA up 19.9% to AED 1.09 billion, and net margin expanding to 9.1%. Capital structure was reinforced by a debut $500 million senior unsecured sukuk in June 2026 (3.2x oversubscribed, listed on LSE ISM), establishing a $1.5 billion sukuk programme alongside inaugural BB+ (S&P) and Ba2 (Moody's) credit ratings. AI capability is delivered through third-party partnerships (Paige for cancer pathology, CONNECTEVE for orthopedic imaging, Genalyte for point-of-care diagnostics), and CAR-T therapy is being localized via a partnership with Caring Cross targeting up to 90% cost reduction.

Name

Burjeel Holdings

Legal name

Burjeel Holdings

Website

https://burjeelholdings.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Private Hospital & Healthcare Network

NAICS

General Medical and Surgical Hospitals (6221), Ambulatory Health Care Services (621), Specialty (except Psychiatric and Substance Abuse) Hospitals (622310)

SIC

Services-Hospitals (8060), Services-Health Services (8000)

akta.pro primary industry

Private/For-Profit Hospital Systems (HLAFAAAF)

Keywords

• Private healthcare services
• Multi-specialty hospitals
• Oncology and transplant care
• Medical tourism services
• Integrated healthcare network

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices7 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales, Others

Revenue model

1. Hospital and Medical Center Services: Burjeel Holdings generates the majority of its revenue from inpatient and outpatient hospital services across its 20 hospitals and 43 medical centers, including tertiary and quaternary care such as oncology, organ transplants, orthopedics, and robotics. Services span primary, secondary, tertiary, and quaternary medical care delivered through a multi-brand portfolio covering all socioeconomic segments. Revenue grew 9.8% to AED 5.5 billion in 2025.
2. Pharmacy Retail: The Group operates 15 pharmacies as part of its integrated healthcare ecosystem, generating revenue from retail pharmaceutical sales. Pharmacies are integrated with the hospital and medical center network, providing a convenient one-stop experience for patients.
3. Specialized Super-Specialty Procedures: Revenue from complex, high-value medical procedures including bone marrow transplants (163+ completed since 2022), organ transplants, robotic surgeries, CAR-T therapies, and advanced oncology treatments. Complex procedure price range is AED 50k–1m. Super-specialty care accounts for >30% of total revenue.
4. Healthcare Claims Management (Claims Care): Burjeel Holdings operates a Claims Care unit providing claims analytics and revenue-cycle management services, including a strategic partnership with Claritev Corporation, generating revenue from processing healthcare claims across the MENA region.
5. Healthcare Network Services (O&M Platform): The Group operates an O&M (Operations & Maintenance) platform providing management services for healthcare facilities across the Gulf and Africa, generating fee income from managing third-party facilities with low capital intensity. Saudi Arabia is the key medium-term expansion region.
6. Sukuk and Capital Markets: Burjeel Holdings completed its inaugural $500 million senior unsecured sukuk (5-year, 7% profit rate) in June 2026, attracting $1.6 billion in orders (3.2x oversubscription). Proceeds used for refinancing existing debt and supporting strategic priorities including advanced clinical care, research, medical education, and AI-enabled healthcare innovation. First MENA healthcare sukuk since 2018.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels7 records

Core offering

Burjeel Holdings operates an integrated, multi-brand private healthcare delivery network spanning primary through quaternary care. Its core business is the provision of inpatient and outpatient hospital and clinical services across 20 hospitals, 43 medical centers, 15 pharmacies, and 11 specialized facilities in the UAE, Oman, and Saudi Arabia, supplemented by retail pharmacy sales, super-specialty complex care (oncology, organ and bone marrow transplantation, robotic surgery, CAR-T therapy, advanced diagnostics), rehabilitation, aesthetics, medical tourism, and a capital-light healthcare O&M management platform.

Product overview

Burjeel Holdings operates as a diversified, multi-brand healthcare services group with a platform-plus-sub-brand architecture. The core offering is a network of 89 healthcare assets (20 hospitals, 43 medical centers, 15 pharmacies, and 11 other facilities) spanning primary to quaternary care across the UAE, Oman, and Saudi Arabia, organized under five principal sub-brands: the premium Burjeel hospital brand, Medeor multi-specialty hospitals, LLH Hospital (cost-effective care), Lifecare community hospitals, and Tajmeel aesthetics clinics, supplemented by Physiotherabia rehabilitation centers. The flagship quaternary facility, Burjeel Medical City in Abu Dhabi, anchors the hub-and-spoke model and houses specialized institutes including the Burjeel Cancer Institute (BCI), Neuro-Oncology Centre, Burjeel Eye Institute, Burjeel Heart Institute, and international collaboration centers (Paley Middle East Clinic, Fetal Medicine & Therapy Center, IFEM Endo, Advanced Gynecology Institute, Northwell Health). Supporting the clinical portfolio are digital health platforms — Oracle Health EMR on Oracle Cloud Infrastructure for AI-enabled clinical operations, the Burjeel Health App for patient-facing services (booking, teleconsultation, EHR, pharmacy), and a telemedicine application co-developed with e& enterprise. Specialized programs include organ transplant, bone marrow transplant, CAR-T cell therapy manufacturing (via Caring Cross partnership), and advanced diagnostics powered by Paige AI (cancer) and CONNECTEVE (orthopedics).

Differentiator

Problem solved

Functional benefit

Brands

• Burjeel Cancer Institute: Oncology hub for the group's comprehensive cancer care network; offers Medical, Radiation, and Surgical Oncology, and Adult/Pediatric Bone Marrow Transplantation. Serves patients across Abu Dhabi, Al Ain, Dubai, Sharjah, Al Dhafra, and Oman; cares for over 5,000 oncology patients annually and delivers over 10,000 radiotherapy sessions.
• Burjeel Heart Institute
• Neuro-Oncology Centre
• Burjeel Eye Institute
• Burjeel Training Academy

Products and services

• Burjeel Hospitals (Premium Brand) Premium hospital brand offering tertiary and quaternary care across 50+ specialties with 700+ doctors and 700+ beds in Abu Dhabi, Al Ain, Dubai, Sharjah, and Oman; targeted at high-income Emiratis and affluent expatriates with a 7-star hospitality service concept.
• Medeor Hospital Multi-specialty hospital brand established in 2015 providing world-class care across 35 specialties with 24x7 emergency services in Abu Dhabi and Dubai, with 170+ doctors and 140+ beds; targeted at middle-income patients and government employees.
• LLH Hospital Cost-effective specialized quality healthcare services in Abu Dhabi with 137 doctors, 21 specialties, and 163 beds; targeted at cost-conscious residents and insured populations.
• Lifecare Hospital Multi-specialty hospitals in Abu Dhabi's Musaffah and Baniyas areas with 105 doctors, 15+ medical and surgical specialties, and 224 beds; targeted at community-level populations with state-of-the-art technology.
• Tajmeel Aesthetics & Cosmetology Premier cosmetology, dermatology, plastic surgery, hair restoration, and aesthetic services brand offering 30+ specialized procedures including advanced aesthetics, dentistry, and surgical care; targets consumers seeking premium aesthetic and regenerative medicine treatments.
• PhysioTherabia Rehabilitation & Physiotherapy Advanced physiotherapy and rehabilitation brand offering the most advanced rehabilitation services in the region, including WalkBot technology and the largest hydrotherapy pool in the UAE; operates standalone physiotherapy centers in Oman (Sohar, Salalah) and Saudi Arabia (Makkah, Riyadh).
• Burjeel Medical City (Quaternary Care Hub) Flagship quaternary care facility of Burjeel Holdings in Abu Dhabi housing Burjeel Cancer Institute, Neuroscience Institute, Burjeel Eye Institute, and international collaboration centers (Paley Middle East Clinic, Fetal Medicine & Therapy Center, IFEM Endo, Advanced Gynecology Institute, Northwell Health); includes Center for Robotic Surgery with Da Vinci XI system and intraoperative MRI.
• Burjeel Cancer Institute Largest cancer care network in the GCC operating under Burjeel Holdings across Abu Dhabi, Al Ain, Dubai, Sharjah, Al Dhafra, and Oman; delivers Medical, Radiation, and Surgical Oncology plus Adult and Pediatric Bone Marrow Transplantation, and serves over 5,000 oncology patients with 10,000+ radiotherapy sessions annually. First ESMO-accredited Integrated Oncology and Palliative Care Center in the UAE.
• Burjeel Heart Institute Cardiovascular institute launched in Al Ain featuring advanced diagnostic and therapeutic facilities led by experienced cardiology specialists, with emphasis on prevention and comprehensive cardiac care.
• Burjeel Eye Institute Specialized ophthalmology and eye surgery institute at Burjeel Medical City offering diagnostic and surgical services across cataract surgery, retinal diseases, glaucoma, and pediatric ophthalmology; led by Emirati ophthalmologists in partnership with Spain's Oftalvist Group.
• Neuro-Oncology Centre Comprehensive multidisciplinary center for brain and nervous system tumors across all ages, established through collaboration between the Burjeel Cancer Institute and Neuroscience Institute at Burjeel Medical City; features intraoperative MRI and neuronavigation systems.
• Burjeel Medical Center Network Network of 43 medical centers (including physiotherapy centers) across Abu Dhabi, Dubai, Northern Emirates, Al Ain, and Saudi Arabia providing primary and secondary care services, integrated with Burjeel's hospital referral network.
• Burjeel Retail Pharmacies 15 pharmacies integrated within the hospital and medical center network, providing retail pharmaceutical sales and over-the-counter products to patients and walk-in consumers; delivers a one-stop experience for prescriptions, refills, and pharmacist consultations.
• CAR-T Cell Therapy (Local Manufacturing) Locally manufactured CAR-T cell therapies for leukemia and lymphoma produced at Burjeel Medical City's planned GMP facility in Abu Dhabi, reducing treatment costs by up to 90% compared to conventional manufacturing; plans to expand to additional diseases and regions including India and Asia.
• Burjeel Claims Care (Healthcare Claims Analytics & Revenue Cycle Management) Healthcare claims analytics and revenue cycle management services deployed across the MENA region in partnership with Claritev Corporation, providing financial operations and claims processing efficiency services to healthcare providers.
• Healthcare Network O&M (Operations & Maintenance) Management Platform Capital-light Operations & Maintenance platform providing fee-based management services for healthcare facilities across the Gulf and Africa; targets facility owners seeking proven operating capability with Saudi Arabia as the key medium-term expansion region.
• Burjeel-e& Telemedicine Platform Cloud-based telemedicine application developed in partnership with e& enterprise that enables remote patient consultations, appointment scheduling, and communication between healthcare professionals for patients across the UAE and MENA region.
• Burjeel Health Mobile App Comprehensive healthcare mobile application offering appointment booking, teleconsultation, electronic health records, medication management, and pharmacy services for patients across Burjeel's network, available on iOS App Store and Google Play.

Quantifiable outcome

• Net profit increased 39.5% to AED 503 million in FY 2025, with Q4 profit jumping 159.9%
• +7 more outcomes

Named customers12 records

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration5 records

AI capability9 records

Feature8 records

Partnerships

22 partnerships are on record, tiered flagship, core and minor.

• Roswell Park Comprehensive Cancer Center (New York)flagshipStrategic or Co-development Partner · 1 July 2026Clinical and academic collaboration launched July 17, 2026 to advance thoracic cancer care in the UAE. The partnership brings world-class expertise from one of the leading US cancer centers to Burjeel Medical City patients, enhancing diagnosis, treatment, and research capabilities in lung and thoracic oncology.
• EDGE GroupcoreGTM or Marketing Partner · 1 July 2026Collaboration to enhance healthcare access for EDGE Group employees and families, providing quality healthcare services across Burjeel's comprehensive network. EDGE Group is a major UAE defense and technology conglomerate.
• e& enterprisecoreStrategic or Co-development Partner · 1 April 2026Strategic partnership to launch telemedicine services, with MoU focused on sustainable healthcare solutions in UAE and MENA region. Includes development of a cloud-based telemedicine application to enhance remote patient care, improve accessibility, and streamline communication between healthcare professionals while reducing carbon footprint through eco-friendly telemedicine practices.
• Paige (US-based AI company)coreTechnology or Integration · 1 April 2026Strategic partnership to deploy FDA-approved AI diagnostic tools (including Paige Prostate Detect and Paige OmniScreen) across Burjeel's MENA network. Collaboration aims to improve cancer diagnosis speed and accuracy, addressing global and regional shortages of pathologists. Burjeel is the first MENA healthcare provider to deploy Paige's AI solutions.
• Korea University Anam HospitalcoreStrategic or Co-development Partner · 1 April 2026MoU signed to enable visiting Korean physicians to perform specialized surgeries in Abu Dhabi at Burjeel Hospital. The Korean Pavilion initiative integrates Korean medical expertise into Burjeel's existing infrastructure, improving access to advanced diagnostics, surgery, and rehabilitation without requiring patients to travel abroad.
• Suzermed Clinic (Türkiye)coreStrategic or Co-development Partner · 1 March 2026Strategic collaboration through Tajmeel brand to establish a specialized hair transplant facility within Tajmeel's flagship clinic in Jumeirah, Dubai. Tajmeel provides clinical space and operational management while Suzermed leads clinical delivery including medical staffing, training, and specialized protocols. Expected to be operational by May 2026.
• CONNECTEVE (South Korea)coreTechnology or Integration · 1 April 2025Partnership to introduce AI-powered knee diagnosis platform (CONNEVO KOA and CONNEVO ALI) at Burjeel Hospital Abu Dhabi. The AI tools aim to improve accuracy of knee treatments and reduce unnecessary surgeries. Platform is the first DoH-approved AI knee diagnosis system in Abu Dhabi. Also reaffirmed during Abu Dhabi Global Health Week 2025.
• Caring CrossflagshipStrategic or Co-development Partner · 1 April 2025Partnership to locally manufacture CAR-T cell therapies in the MENA region, reducing costs by up to 90%. The collaboration aims to establish a GMP manufacturing facility in Abu Dhabi processing up to 200 samples simultaneously, initially focusing on leukemia and lymphoma with plans to expand to other diseases and regions including India and Asia.
• GenalytecoreTechnology or Integration · 1 April 2025Strategic partnership during Abu Dhabi Global Health Week 2025 to deploy Genalyte's Merlin diagnostic system across Burjeel's healthcare network. The system, pending FDA clearance, aims to provide rapid diagnostics especially in remote and underserved regions, improving healthcare delivery through innovative diagnostic technology.
• Oftalvist (Spain)coreStrategic or Co-development Partner · 1 April 2025MoU signed during Burjeel Eye Institute launch at Burjeel Medical City for collaboration in comprehensive eye care. Oftalvist is a renowned ophthalmology group in Spain providing expertise and clinical collaboration for the Burjeel Eye Institute.
• Etihad AirwayscoreGTM or Marketing Partner · 1 March 2025MoU to promote Abu Dhabi as a medical tourism hub, creating referral pathways for international patients and providing priority access to healthcare for Etihad employees. Collaboration aims to enhance access to quality treatment and patient experience while supporting Abu Dhabi's positioning as a global healthcare destination.
• Black Group Investment HoldingminorStrategic or Co-development Partner · 1 March 2025Singaporean firm invested in developing a healthcare facility in Malaysia, with Burjeel Holdings as a strategic partner in the broader collaboration ecosystem for healthcare development in the MENA and Asia-Pacific regions.
• Egypt Ministry of HealthcoreStrategic or Co-development Partner · 1 February 2025MoU signed at Arab Health 2025 to develop a comprehensive Bone Marrow Transplant (BMT) program and improve oncology care in Egypt and Africa. Includes establishing a transplant unit, providing extensive training, and advancing research in cancer therapies like CAR-T cell therapy.
• Oracle HealthcoreTechnology or Integration · 1 February 2025Launch of one of the largest Electronic Medical Record (EMR) platforms in the MENA region, utilizing Oracle Health on Oracle Cloud Infrastructure. Platform aims to transform patient care, improve clinical outcomes, and enhance operational efficiency across Burjeel's network with initial deployment at key facilities and plans for AI integration and data-driven healthcare.
• Claritev CorporationcoreTechnology or Integration · 1 January 2025Strategic partnership between Claritev Corporation and Burjeel Holdings' Claims Care unit to deploy advanced claims-analytics and revenue-cycle management solutions across the Middle East and North Africa region, improving financial operations and claims processing efficiency.
• Harvard Medical School / Dana-Farber Cancer InstituteflagshipStrategic or Co-development Partner · 1 January 2025Burjeel Cancer Institute launched the UAE's first accredited fellowship program in oncology in partnership with Harvard Medical School and Dana-Farber Cancer Institute. This is a landmark medical education collaboration bringing world-class oncology training to the UAE.
• Axiom SpacecoreStrategic or Co-development Partner · 1 November 2024MoU to collaborate on conducting medical research and testing new technologies in space, studying effects of microgravity on the human body. First joint initiative involves sending medical capabilities to space to observe impact on biomarkers and drug quality, with tests on Axiom Mission 4. Also enabling insulin-dependent diabetics to travel to space ('Suite Ride' study).
• Abu Dhabi University (ADU)coreStrategic or Co-development Partner · 1 November 2024MoU to collaborate on advancing clinical research and enhancing academic programs in health sciences in the UAE. ADU students and faculty gain access to Burjeel's clinical facilities and research infrastructure.
• Response Plus MedicalcoreGTM or Marketing Partner · 1 November 2024Joint launch of $1 million Human Energy Health and Wellbeing Award at ADIPEC 2024 to promote workplace wellness in the global energy sector. The award aims to encourage AI-driven initiatives to enhance mental and physical health among energy industry employees.
• Gulf Medical University (GMU)coreStrategic or Co-development Partner · 1 October 2024MoU to strengthen collaboration in medical education, research, and clinical training. GMU students gain access to Burjeel Holdings' hospitals and facilities including Burjeel Medical City for clinical training, internships, and joint research projects. Partnership supports UAE's vision for healthcare excellence through innovative residency, fellowship, and professional development programs.
• OncoHelix-CoLabcoreTechnology or Integration · 1 May 2024Laboratory launched at Burjeel Medical City in partnership with OncoHelix-CoLab to enhance regional molecular testing capabilities for precision oncology. Canadian precision oncology provider establishing laboratory infrastructure to support cancer diagnosis and treatment planning.
• Department of Health – Abu Dhabi (DoH)coreStrategic or Co-development Partner · 1 October 2023MoU signed during GITEX Global Week 2023 to collaborate on leveraging AI solutions in emergency departments (EDs). The partnership aims to improve patient care, optimize resource allocation, and enhance operational efficiency through data-driven AI technologies. Part of Abu Dhabi's broader efforts to advance healthcare digital infrastructure and position itself as an innovation hub for healthcare.

Scale indicators16 records

Recent moves11 records

Expansion highlights7 records

Direct peers

• NMC Healthcare: One of the largest private healthcare operators in the UAE with hospitals, medical centers, and pharmacies. Direct competitor in the multi-brand, multi-segment private hospital market that Burjeel operates in across UAE and GCC.
• Aster DM Healthcare: UAE-headquartered private hospital and clinic operator with GCC-wide network spanning hospitals, clinics, and pharmacies. Comparable multi-segment model and similar exposure to medical tourism and Indian expatriate patient base.
• VPS Healthcare: UAE-based private healthcare group operating hospitals, medical centers, and clinics across the GCC and India. Closest direct peer by footprint and multi-brand positioning targeting similar expatriate and local populations.
• Mediclinic Middle East: Subsidiary of Mediclinic International (now part of Remgro) operating premium private hospitals and clinics in UAE. Competes with Burjeel's premium segment on complex care, technology, and international patient referrals.
• Saudi German Hospitals Group: Major private hospital operator across Saudi Arabia, UAE, Egypt, and Yemen under Batterjee family. Comparable multi-country private hospital group; represents a key competitor for Burjeel's stated KSA expansion ambitions.
• Thumbay Group (GMC Healthcare): UAE-based private healthcare, education, and pharmacy conglomerate operating hospitals, clinics, and pharmacies across the GCC. Comparable multi-segment approach targeting expatriates and medical tourists at similar price points.

Broad incumbents

• Dr. Sulaiman Al Habib Medical Group: Largest private healthcare provider in Saudi Arabia with extensive hospital and clinic network. Sets benchmark for scaled GCC private healthcare and is the dominant competitor Burjeel must contend with to capture KSA market share.
• Cleveland Clinic Abu Dhabi: Mubadala-owned quaternary care hospital under Cleveland Clinic brand license. Competes with Burjeel Medical City on ultra-premium, complex specialty cases and medical tourism positioning in Abu Dhabi.

Regional players

• Mouwasat Medical Services: Saudi-listed private hospital and clinic operator primarily serving Saudi Arabia with growing footprint. Comparable in scale and super-specialty focus; relevant peer for benchmarking KSA expansion economics.

Emerging players

• King's College Hospital London (Dubai): UK NHS-affiliated premium hospital in Dubai Hills. Competes with Burjeel's premium Dubai facilities on international brand, complex care, and medical tourism referrals from UK-trained physicians.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/BurjeelHoldings
• YouTubeyoutube.com/channel/UCXUzNk5Sz5bXvLvOi9hIvrg
• Facebookfacebook.com/BurjeelHoldings
• LinkedInlinkedin.com/company/burjeel-holdings
• Instagraminstagram.com/burjeelholdings

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries7 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Burjeel Holdings